Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Deferred Tax Liabilities: $3,397M in FY2025, up 40.4% from a year earlier.
Latest, FY2025
3,397
Period ended Dec 31, 2025
Change on a year earlier
+40.4%
2,419 in FY2024
History
10 years
Since FY2016
Sources
8
Documents cited below
Where the FY2025 figure comes from
Source: Novartis 20-F (0001114448-26-000004, filed 2026-02-04) ↗
Reported in Postgres DB + Form 6-K.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Deferred Tax Liabilities ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3,397 | +40.4% | Novartis 20-F (0001114448-26-000004, filed 2026-02-04) ↗ |
| FY2024 | Dec 31, 2024 | 2,419 | +7.6% | Novartis 20-F (0001370368-25-000004, filed 2025-01-31) ↗ |
| FY2023 | Dec 31, 2023 | 2,248 | -16.3% | Novartis 20-F (0001370368-24-000004, filed 2024-01-31) ↗ |
| FY2022 | Dec 31, 2022 | 2,686 | -12.5% | Novartis 20-F (0001370368-23-000006, filed 2023-02-01) ↗ |
| FY2021 | Dec 31, 2021 | 3,070 | -2.3% | Novartis 20-F (0001370368-22-000010, filed 2022-02-02) ↗ |
| FY2020 | Dec 31, 2020 | 3,141 | -46.5% | Novartis 20-F (0001370368-22-000010, filed 2022-02-02) ↗ |
| FY2019 | Dec 31, 2019 | 5,867 | -21.5% | Novartis 20-F (0001370368-20-000003, filed 2020-01-29) ↗ |
| FY2018 | Dec 31, 2018 | 7,475 | +44.6% | Novartis 20-F (0001370368-19-000002, filed 2019-01-30) ↗ |
| FY2017 | Dec 31, 2017 | 5,168 | -22.4% | Novartis 6-K (0001370368-18-000005, filed 2018-01-24) ↗ |
| FY2016 | Dec 31, 2016 | 6,657 | – | Novartis 6-K (0001370368-18-000005, filed 2018-01-24) ↗ |
Cite this data
StockData. (2026). Novartis Deferred Tax Liabilities ($M), annual FY2016–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/db-bs-dtl
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.